Innovent Announces First Patient Dosed in the Phase 3 Clinical Study (STAR) of Efdamrofusp Alfa (IBI302), a First-in-class Ophthalmic Anti-VEGF and Anti-Complement Bispecific Fusion Protein for the Treatment of Neovascular Age-related Macul ...Middle East

ROCKVILLE, Md. and SUZHOU, China, Oct. 8, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune,...

Hence then, the article about innovent announces first patient dosed in the phase 3 clinical study star of efdamrofusp alfa ibi302 a first in class ophthalmic anti vegf and anti complement bispecific fusion protein for the treatment of neovascular age related macul was published today ( Monday 09/10/2023 - 03:08 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Innovent Announces First Patient Dosed in the Phase 3 Clinical Study (STAR) of Efdamrofusp Alfa (IBI302), a First-in-class Ophthalmic Anti-VEGF and Anti-Complement Bispecific Fusion Protein for the Treatment of Neovascular Age-related Macul )

Also on site :

• Americans are feeling inflation’s pinch into the holiday weekend. Here’s where prices are rising the most
• Masculinity Satire Australian Animated Series ‘Finally, a Show About Men!’ Bows on YouTube (EXCLUSIVE)
• Amazon’s 'Very Soft' and 'Breathable' Matching Cotton Lounge Set Is Just $10, and It Comes in 15 Styles